Phase II Tria l o f the Ant iangiogenic Agent Thal idomide in Pat ients With Recurrent High-Grade Gl iomas
暂无分享,去创建一个
W. Yung | P. Wen | P. Black | H. Fine | J. Loeffler | A. Kyritsis | V. Levin | W. Figg | K. Jaeckle | R. Kaplan | J. Pluda
[1] Y. Ozyazgan,et al. Thalidomide in the Treatment of the Mucocutaneous Lesions of the Behcet Syndrome , 1998, Annals of Internal Medicine.
[2] R. Miniero,et al. The role of thalidomide in the treatment of refractory chronic graft-versus-host disease following bone marrow transplantation in children , 1998, Bone Marrow Transplantation.
[3] G. Trinchieri,et al. Inhibition of IL-12 production by thalidomide. , 1997, Journal of immunology.
[4] R. D'Amato,et al. Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization. , 1997, Experimental eye research.
[5] J. Fahey,et al. Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. , 1997, The New England journal of medicine.
[6] P. Wen,et al. Viral vector-mediated transduction of a modified platelet factor 4 cDNA inhibits angiogenesis and tumor growth , 1997, Nature Medicine.
[7] William Arbuthnot Sir Lane,et al. Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth , 1997, Cell.
[8] T. Mikkelsen,et al. Inhibition of angiogenesis in human glioblastomas by chromosome 10 induction of thrombospondin-1. , 1996, Cancer research.
[9] D. Hanahan,et al. Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis , 1996, Cell.
[10] B. Teicher,et al. Comparison of several antiangiogenic regimens alone and with cytotoxic therapies in the Lewis lung carcinoma , 1996, Cancer Chemotherapy and Pharmacology.
[11] B. Teicher,et al. Potentiation of cytotoxic cancer therapies by TNP‐470 alone and with other anti‐angiogenic agents , 1994, International journal of cancer.
[12] Michael S. Pepper,et al. The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumour growth , 1994, Nature.
[13] A. Ullrich,et al. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant , 1994, Nature.
[14] R. D'Amato,et al. Thalidomide is an inhibitor of angiogenesis. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[15] H. Fine,et al. Primary Central Nervous System Lymphoma , 1993, Annals of Internal Medicine.
[16] B. Teicher,et al. Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease. , 1992, Cancer research.
[17] Georg Breier,et al. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo , 1992, Nature.
[18] E. Keshet,et al. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis , 1992, Nature.
[19] L. Deangelis,et al. Combined modality therapy for primary CNS lymphoma. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] Y. Osada,et al. Inhibition of angiogenesis and tumor growth by a synthetic laminin peptide, CDPGYIGSR-NH2. , 1991, Cancer research.
[21] D. Ingber,et al. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth , 1990, Nature.
[22] E. A. Chiocca,et al. Inhibition of growth and angiogenesis of human neurofibrosarcoma by heparin and hydrocortisone. , 1990, Journal of neurosurgery.
[23] T. Cascino,et al. Response criteria for phase II studies of supratentorial malignant glioma. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] P. Black,et al. Coexpression of platelet-derived growth factor (PDGF) and PDGF-receptor genes by primary human astrocytomas may contribute to their development and maintenance. , 1990, The Journal of clinical investigation.
[25] J. Folkman. What is the evidence that tumors are angiogenesis dependent? , 1990, Journal of the National Cancer Institute.
[26] J. Cairncross,et al. Successful chemotherapy for recurrent malignant oligodendroglioma , 1988, Annals of neurology.
[27] D. Norman,et al. Criteria for evaluating patients undergoing chemotherapy for malignant brain tumors. , 1977, Journal of neurosurgery.
[28] J. Folkman,et al. Tumor angiogenesis: a quantitative method for histologic grading. , 1972, Journal of the National Cancer Institute.
[29] J. Folkman. Tumor angiogenesis: therapeutic implications. , 1971, The New England journal of medicine.